For older people and frail people, the long-term benefit of medicines reduces and the potential for harm from adverse effects increases. When the benefit–risk balance changes in this way, medicine review and optimisation are important to simplify the therapeutic regimen, reduce inappropriate medicines and minimise risks. In this article, pharmacist prescriber Linda Bryant uses two case studies to illustrate important considerations during medicine reviews
Saving lives with lower targets for low-density lipoprotein cholesterol
+Practice
In print
HEARTBEAT
Saving lives with lower targets for low-density lipoprotein cholesterol
Wednesday 12 October 2022, 12:40 AM

[Image: ECG supplied]
Consultant cardiologist Chris Ellis discusses the secondary prevention options available to a patient who experienced a non-ST-elevation myocardial infarction two years ago
Key points, For cardiovascular risk prevention, science has conclusively demonstrated that lower is better for low-density lipoprotein cholesterol.
Rosuvastatin, Pract Green w Pale Yellow
Kia ora and welcome to New Zealand Doctor Rata Aotearoa
Not a subscriber? Unlock this article by subscribing here.
References
1. Packard C, Chapman MJ, Sibartie M, et al. Intensive low-density lipoprotein cholesterol lowering in cardiovascular disease prevention: opportunities and challenges. Heart 2021;107(17):1369–75.
2. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020;41(1):11188.